Forwards-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment—a pharmacokinetic-pharmacodynamic study

HIGHLIGHTS

  • who: L. M. Paterson from the Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK have published the paper: FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatmentu2014a pharmacokinetic-pharmacodynamic study, in the Journal: (JOURNAL) of 16/Dec/2021
  • what: The authors aim for 30 mg as a minimum target dose in the indication , but uncertainty exists around the target maintenance dose. The primary estimand for the primary objective is described by the following attributes: All participants . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?